Clinical trial
Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus…
NCT00127777 · University Hospital, Saarland, Other · Unknown status
Key facts
| NCT number | NCT00127777 |
|---|---|
| Title | Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) |
| Official title | Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection |
| Lead sponsor | University Hospital, Saarland, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Amantadine sulphate (in addition to standard treatment) |
| Enrollment | 700 |
| Start date | Jul 1, 2002 |
| Completion | Dec 1, 2006 |
| First posted | Aug 8, 2005 |
| Last update posted | Aug 25, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: